The best way to predict future is to invent it.
- Alan Kay
Syntab Therapeutics is committed to developing innovative immunooncologic therapeutics. Our lead compound is ISEr Y9, which will soon reach the IND-ready status.
Syntab Therapeutics plans to enter into different license agreements for its portfolio products in due time.